Terms: = Thyroid cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
57 results:
1. Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022.
Okizaki A; Nishiyama Y; Inui Y; Otsuka H; Takanami K; Nakajo M; Nakatani K; Nogami M; Hirata K; Maeda Y; Yoshimura M; Wakabayashi H
Ann Nucl Med; 2024 Apr; 38(4):315-327. PubMed ID: 38421515
[TBL] [Abstract] [Full Text] [Related]
2. Drug-induced inhibition of HMGA and ezh2 activity as a possible therapy for anaplastic thyroid carcinoma.
De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
[TBL] [Abstract] [Full Text] [Related]
3. ezh2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract] [Full Text] [Related]
4. A clinically useful and biologically informative genomic classifier for papillary thyroid cancer.
Craig S; Stretch C; Farshidfar F; Sheka D; Alabi N; Siddiqui A; Kopciuk K; Park YJ; Khalil M; Khan F; Harvey A; Bathe OF
Front Endocrinol (Lausanne); 2023; 14():1220617. PubMed ID: 37772080
[TBL] [Abstract] [Full Text] [Related]
5. Modulation of ezh2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic thyroid cancer.
de Mello DC; Saito KC; Cristovão MM; Kimura ET; Fuziwara CS
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175580
[TBL] [Abstract] [Full Text] [Related]
6. FAK-mediated phosphorylation at Y464 regulates p85β nuclear translocation to promote tumorigenesis of ccRCC by repressing RB1 expression.
Zhang Y; He B; Zhang D; Zhang Y; Chen C; Zhang W; Yang S; Yao M; Cui G; Gu J; Wang T; Lin Z; Fan Y; Xiong Z; Hao Y
Cell Rep; 2023 Mar; 42(3):112188. PubMed ID: 36857183
[TBL] [Abstract] [Full Text] [Related]
7. Validation of ezh2 Inhibitor Efficiency in Anaplastic thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract] [Full Text] [Related]
8. Genomic Profiling Reveals the Variant Landscape of Sporadic Parathyroid Adenomas in Chinese Population.
Tao X; Xu T; Lin X; Xu S; Fan Y; Guo B; Deng X; Jiao Q; Chen L; Wei Z; Chen C; Yang W; Zhang Z; Yu X; Yue H
J Clin Endocrinol Metab; 2023 Jun; 108(7):1768-1775. PubMed ID: 36611251
[TBL] [Abstract] [Full Text] [Related]
9. circezh2
Su Z; Zhang M; Luo H; Zhong J; Tan J; Xu Y; Pan X; Zeng H; Nie L; Xu M; Chen N; Chen X; Zhou Q
Cancer Sci; 2023 Apr; 114(4):1378-1395. PubMed ID: 36519785
[TBL] [Abstract] [Full Text] [Related]
10. Contribution and clinical relevance of germline variation to the cancer transcriptome.
Pereira B; Labrot E; Durand E; Korn JM; Kauffmann A; Campbell CD
BMC Cancer; 2022 Jun; 22(1):675. PubMed ID: 35725412
[TBL] [Abstract] [Full Text] [Related]
11. ezh2 promotes TRβ lysine methylation-mediated degradation in hepatocellular carcinoma.
Park SC; Lee JM
Genes Genomics; 2022 Mar; 44(3):369-377. PubMed ID: 34851506
[TBL] [Abstract] [Full Text] [Related]
12. LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target ezh2 by sponging miR-150-5p.
Guo K; Qian K; Shi Y; Sun T; Wang Z
Cell Death Dis; 2021 Nov; 12(12):1097. PubMed ID: 34811354
[TBL] [Abstract] [Full Text] [Related]
13. LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer.
Zhang M; Yang L; Hou L; Tang X
Bioengineered; 2021 Dec; 12(2):9239-9250. PubMed ID: 34806925
[TBL] [Abstract] [Full Text] [Related]
14. CircGSK3B promotes RORA expression and suppresses gastric cancer progression through the prevention of ezh2 trans-inhibition.
Ma X; Chen H; Li L; Yang F; Wu C; Tao K
J Exp Clin Cancer Res; 2021 Oct; 40(1):330. PubMed ID: 34666800
[TBL] [Abstract] [Full Text] [Related]
15. Single-Cell Analyses Reveal Mechanisms of cancer Stem Cell Maintenance and Epithelial-Mesenchymal Transition in Recurrent Bladder cancer.
Wang H; Mei Y; Luo C; Huang Q; Wang Z; Lu GM; Qin L; Sun Z; Huang CW; Yang ZW; Chen J; Yin W; Qian CN; Zeng J; Chen L; Leng Q; Guo Y; Jia G
Clin Cancer Res; 2021 Nov; 27(22):6265-6278. PubMed ID: 34526362
[TBL] [Abstract] [Full Text] [Related]
16. Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.
Hamamoto Y; Kukita Y; Kitamura M; Kurashige M; Masaie H; Fuji S; Ishikawa J; Honma K; Wakasa T; Hanamoto H; Hirokawa M; Suzuki A; Morii E; Nakatsuka SI
Histopathology; 2021 Oct; 79(4):521-532. PubMed ID: 33829512
[TBL] [Abstract] [Full Text] [Related]
17. SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell carcinoma.
Gandhi JS; Alnoor F; Sadiq Q; Solares J; Gradowski JF
Pathol Res Pract; 2021 Mar; 219():153341. PubMed ID: 33581550
[TBL] [Abstract] [Full Text] [Related]
18. LINC01116 facilitates colorectal cancer cell proliferation and angiogenesis through targeting ezh2-regulated TPM1.
Liang W; Wu J; Qiu X
J Transl Med; 2021 Jan; 19(1):45. PubMed ID: 33499872
[TBL] [Abstract] [Full Text] [Related]
19. SMARCB1-deficient carcinomas of the head and neck region: a cytopathologic characterization.
Kezlarian BE; Lin O; Dogan S
J Am Soc Cytopathol; 2020; 9(6):494-501. PubMed ID: 32839151
[TBL] [Abstract] [Full Text] [Related]
20. ezh2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract] [Full Text] [Related]
[Next]
